CLU and Parkinson disease: Another study reported significant downregulation of clusterin, apolipoprotein A1, and complement C1r subcomponent in EVs from the plasma of PD patients at Hoehn and Yahr (HY) stages II and III compared to healthy controls [67], suggesting that these proteins may also be used as candidate biomarkers for PD.